Showing 141-150 of 3024 results for "".
Deepening Our Understanding of the Science Behind Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/deepening-our-understanding-of-the-science-behind-multiple-sclerosis/30207/- Expert Opinionhttps://practicalneurology.com/columns/practice-management/expert-opinion/31295/Management of Acute Seizures and Long-Term Antiepileptic Therapy: A Case StudyIn a recent article by Niranjan Siva, MD, and Amit Verma, MD, published in *Practical Neurology*, a 24-year-old male experienced two first-time generalized tonic-clonic seizures without aura within a two-hour period. Initi
Multiple Sclerosis Minute: Telemedicine and Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/multiple-sclerosis-minute-telemedicine-and-multiple-sclerosis/30116/Telemedicine is acceptable to patients and clinicians in the continuum of clinic-to-in-home care and reduces barriers to care.Clarifying the Role of Vitamin D in Multiple Sclerosis Risk and Prevention
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/clarifying-the-role-of-vitamin-d-in-multiple-sclerosis-risk-and-prevention/30314/Recent findings reinforce the link between vitamin D levels and risk of multiple sclerosis.Disease Awareness: Multiple Sclerosis and Parkinson's
https://practicalneurology.com/columns/practice-management/disease-awareness-multiple-sclerosis-and-parkinsons/30781/Filling the Gaps in the Multiple Sclerosis Treatment Landscape
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/filling-the-gaps-in-the-multiple-sclerosis-treatment-landscape/30372/The addition of a potential breakthrough agent may change the treatment arena, but wellness and early treatment remain the foundation of effective care.Paraclinical Optic Nerve Tests in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/paraclinical-optic-nerve-tests-in-multiple-sclerosis/54605/Confirming optic neuritis—and, by extension, optic nerve involvement as a distinct anatomic region within the McDonald criteria—requires careful integration of the individual’s history, a thorough neuro-ophthalmic examination, and judicious interpretation of diagnostic tests.RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
https://practicalneurology.com/programs/practical-neurology/trials-in-2/35433/Christopher Moertel, MD, Medical Director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs at the University of Minnesota provides an overview of the ReNeu clinical trial which evaluated the safety, effectiveness, and tolerability of Gomekli in children aged ≥2 years and adults.The Role of Advanced Genomic Testing in the Diagnosis and Treatment of Neurologic Conditions
https://practicalneurology.com/programs/practical-neurology/the-role-of-advanced-genomic-testing-in-the-diagnosis-and-treatment-of-neurologic-conditions/30100/Paul Kruszka, MD, Chief Medical Officer at GeneDx, discusses advanced genomic testing, emphasizing how these tests are used to guide diagnosis and treatment decisions associated with neurodevelopmental conditions, including genetic variants associated with epilepsy.Physicians with Substance Use Disorder, Part II: Available Treatment and Recovery Options
https://practicalneurology.com/columns/practice-management/physicians-with-substance-use-disorder-part-ii-available-treatment-and-recovery-options/30091/Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of treatment and recovery options available to physicians with substance use disorder, including peer-to-peer support, medication, and Physician Health Programs.